logo-loader
viewSummit Therapeutics PLC

AIM - Cancellation - Summit Therapeutics PLC

RNS Number : 7948D
AIM
24 February 2020
 

NOTICE

 

24/02/2020

 

NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM - XLON

 

At the request of the Company the following securities have been cancelled from trading on AIM with effect from the time and date of this notice.

 

SUMMIT THERAPEUTICS PLC

213800NRW8AOMYMTBD89

ORDINARY SHARES OF 1P EACH, FULLY PAID

(BN40HZ0)(GB00BN40HZ01)

SUMT THER/PAR VTG FDP 0.01

 

If you have any queries or require further information, please contact the company's nominated adviser +44 (0)20 7213 0880.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AMOUASVRRRUUUAR

Quick facts: Summit Therapeutics PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

on 10/2/20